Skip to Content
Morningstar

Fresenius Medical Care AG & Co. KGaA ADR FMS Stock Quote

Morningstar Rating
| Rating as of

NYSE:FMS

Morningstar‘s Stock Analysis FMS

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Investor
Is it the right time to buy or sell?
Find out with Morningstar Investor

1-Star Price

INVESTOR

5-Star Price

INVESTOR

Economic Moat

INVESTOR

Capital Allocation

INVESTOR

Fresenius Shares Remain Cheap While Changing CEOs and Awaiting Transformation Plan

Julie Utterback, CFA Senior Equity Analyst

Analyst Note

| Julie Utterback, CFA |

Narrow-moat Fresenius Medical Care announced that Dr. Carla Kriwet has stepped down after only a couple months at the helm as CEO due to "strategic differences" with its boards. The company's CFO (and deputy CEO and chief transformation officer), Helen Giza, will take over as head of the company. We do not anticipate changing our fair value estimates for Fresenius Medical Care or large stakeholder Fresenius SE at this juncture, but this move points to more uncertain times for shareholders, as management has yet to reveal details on how it plans to unlock the significant value we see within the Fresenius organizations.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics FMS

More

Company Profile FMS

Business Description

Fresenius Medical Care is the largest dialysis company in the world, treating about 345,000 patients from over 4,100 clinics across the globe as of September 2021. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market and benefits from being the world's only fully integrated dialysis business. Services account for roughly 80% of firmwide revenue, including care coordination and ancillary operations, while products account for the other roughly 20%. Products typically enjoy a higher margin, making them a strong contributor to the bottom line.

Contact
Else-Kroener-Strasse 1
Bad Homburg, HE, 61352, Germany
T +49 61726090
Sector Healthcare
Industry Medical Care Facilities
Most Recent Earnings Sep 30, 2022
Fiscal Year End Dec 31, 2022
Employees 122,758

Related News FMS

Market Update

The Best- and Worst-Performing Stocks: Q3 2022

Solar stocks shine, and retail remains buoyant. Chinese tech names and European healthcare get battered.
Jakir Hossain
Market Update

Strong U.S. Dollar a Headwind to Earnings Growth

Dollar appreciation will result in lower short-term earnings growth but typically won’t have a meaningful effect on long-term intrinsic valuation.
David Sekera
Market Update

Markets Brief: Stocks Close July With Best Rally Since November 2020; Jobs Report Ahead

First Solar, Sunrun gain on climate bill news. Disappointing earnings results send Roku shares plunging.
Jakir Hossain
Stock Strategist Industry Reports

Healthcare Policy Changes Could Result in Opportunities

Expanded insurance rolls would be good news for the managed-care organizations and service providers we cover.
Julie Utterback
Stock Strategist

Home Dialysis to Benefit These Undervalued Providers

DaVita and Fresenius are best positioned to capture the incremental profits from home therapy.
Jake Strole
US Videos

A Cheap, Promising Healthcare Opportunity

Both DaVita and Fresenius are well positioned among dialysis service providers, but only one of those stocks is undervalued today.
Jake Strole
Stock Strategist

Dominance in Dialysis Digs DaVita a Moat

We think the company's advantages will protect shareholder returns over the long run.
Jake Strole
Stock Strategist

Baxter's Headwinds Mostly Temporary

The company faces near-term challenges after the split, but we still like its moat.
Michael Waterhouse
Commentary

Pfizer's Acquisition of Hospira Strengthens Its Moat at a Fair Price

Despite the high 39% premium to Hospira's stock price, we believe the acquisition price is justified based on Pfizer's ability to unlock more value with its global reach.
Damien Conover
Stock Strategist

A Shift in Health-Care M&A Activity

Recent deals have been driven more by tax strategies than therapeutic synergies.
Basili Alukos
Stock Strategist

Moats and Growth Drivers Look Solid for Post-Split Baxter

Focus remains on hemophilia competition, but Baxter's comprehensive product portfolios are unmatched.
Karen Andersen
Credit Insights

Treasury Bonds Take It on the Chin

Strong job growth sent Treasury rates upward, but corporate credit spreads held steady on a flood of new issues.
David Sekera
Stock Strategist

Strong Pipeline Helps Protect Baxter's Wide Moat From Competition

The diversified health-care firm remains remarkably profitable in tough industries.
Karen Andersen
Credit Insights

What a Difference One Economic Data Point Makes

As soon as the employment number was released Friday morning, everyone immediately became a buyer of corporate bonds.
David Sekera
Stock Strategist Industry Reports

Patient Trends Improving, but Reimbursement Outlook Remains Bleak for Health Service Providers

Greater accountability creates a new level of operating uncertainty.
Michael Waterhouse
Berkshire Coverage

Berkshire's 4Q Transactions Have Ted Weschler's Fingerprints All Over Them

The company made a number of significant purchases in the quarter while selling off small amounts of long-held legacy positions.
Drew Woodbury
Credit Insights

All Quiet on the European Front

We are cautious that the current credit rebound will persist.
David Sekera
Investing Specialists

Buffett's Lieutenants Impact Berkshire's Most Recent Purchases

DIRECTV stands out among Berkshire's fourth-quarter stock purchases; IBM and Wells Fargo are other big buys.
The Morningstar Ultimate Stock-Pickers Team
Credit Insights

Markets Rally When Europe's Quiet

As investors focus on individual credit quality, they like what they see.
David Sekera
Stock Strategist Industry Reports

Why Dialysis Remains an Attractive Business

The dialysis industry is in a state of flux, but business models remain intact.
Bill Buhr